BioXcel Therapeutics, Inc. (BTAI)
0.1814
-0.54
(-74.76%)
USD |
NASDAQ |
Aug 28, 16:00
0.1666
-0.01
(-8.16%)
After-Hours: 20:00
BioXcel Therapeutics Enterprise Value : 96.33M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 96.33M |
| August 27, 2026 | 113.15M |
| August 26, 2026 | 115.07M |
| August 25, 2026 | 113.88M |
| August 24, 2026 | 114.46M |
| August 21, 2026 | 115.81M |
| August 20, 2026 | 115.65M |
| August 19, 2026 | 116.55M |
| August 18, 2026 | 115.45M |
| August 17, 2026 | 118.51M |
| August 14, 2026 | 127.90M |
| August 13, 2026 | 126.02M |
| August 12, 2026 | 123.83M |
| August 11, 2026 | 119.82M |
| August 10, 2026 | 119.70M |
| August 07, 2026 | 118.88M |
| August 06, 2026 | 116.64M |
| August 05, 2026 | 116.96M |
| August 04, 2026 | 117.59M |
| August 03, 2026 | 117.18M |
| July 31, 2026 | 115.94M |
| July 30, 2026 | 115.47M |
| July 29, 2026 | 115.77M |
| July 28, 2026 | 117.10M |
| July 27, 2026 | 117.79M |
| Date | Value |
|---|---|
| July 24, 2026 | 117.18M |
| July 23, 2026 | 117.89M |
| July 22, 2026 | 118.19M |
| July 21, 2026 | 118.75M |
| July 20, 2026 | 118.28M |
| July 17, 2026 | 118.43M |
| July 16, 2026 | 117.89M |
| July 15, 2026 | 119.50M |
| July 14, 2026 | 122.89M |
| July 13, 2026 | 118.27M |
| July 10, 2026 | 116.24M |
| July 09, 2026 | 116.88M |
| July 08, 2026 | 115.76M |
| July 07, 2026 | 123.21M |
| July 06, 2026 | 125.09M |
| July 02, 2026 | 133.85M |
| July 01, 2026 | 133.54M |
| June 30, 2026 | 134.79M |
| June 29, 2026 | 121.01M |
| June 26, 2026 | 118.58M |
| June 25, 2026 | 116.95M |
| June 24, 2026 | 118.58M |
| June 23, 2026 | 117.22M |
| June 22, 2026 | 118.31M |
| June 18, 2026 | 115.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 591.10M |
| Amgen, Inc. | 277.08B |
| Anika Therapeutics, Inc. | 269.22M |
| BioCryst Pharmaceuticals, Inc. | 2.990B |
| Imunon, Inc. | 8.446M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.71M |
| Revenue (Quarterly) | 0.182M |
| Total Expenses (Quarterly) | 14.90M |
| EPS Diluted (Quarterly) | -0.4856 |
| Gross Profit Margin (Quarterly) | 78.02% |
| Profit Margin (Quarterly) | -8.08K% |
| Earnings Yield | -2.33K% |
| Normalized Earnings Yield | -2022.11 |